Quick Answer
Kalaris Therapeutics, Inc. reported Total Revenue of $165.0 thousand for fiscal year 2019.
Kalaris Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Revenue (ASC 606) | — | — | — | — | — | — |
| Net Income | -$43.44M +37.2% |
-$69.17M +63.7% |
-$190.42M -12.9% |
-$168.71M +1.9% |
-$171.96M -146.4% |
-$69.78M -192.7% |
| Diluted EPS | -$2.85 +94.5% |
-$51.77 -23.0% |
-$42.09 -1813.2% |
-$2.20 +19.7% |
-$2.74 | — |
| Total Assets | $121.74M +1875.6% |
$6.16M -96.8% |
$190.80M -31.1% |
$277.08M -3.3% |
$286.59M -22.7% |
$370.82M +166.0% |
| Cash and Equivalents | $98.05M +5882.6% |
$1.64M -98.2% |
$90.12M -15.1% |
$106.09M -47.4% |
$201.66M +64.4% |
$122.66M +100.8% |
| Stockholders Equity | $78.81M +181.6% |
-$96.62M -114.6% |
-$45.02M -120.1% |
$224.52M -0.3% |
$225.27M -36.2% |
$353.06M +785.5% |
| R&D Expense | $30.75M -31.7% |
$45.04M -66.2% |
$133.07M +11.9% |
$118.87M -1.5% |
$120.73M +143.1% |
$49.66M +205.7% |
| Operating Income | -$46.15M +10.8% |
-$51.73M +74.1% |
-$199.90M -16.8% |
-$171.20M -0.8% |
-$169.82M -138.1% |
-$71.31M -167.1% |
| Shares Outstanding | 22.90M +1588.4% |
1.36M -72.7% |
4.96M -94.7% |
93.09M +46.5% |
63.57M +2.6% |
61.93M +2849.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$11.89M | +68.8% | -4.8% |
| Diluted EPS | September 30, 2025 | -$0.64 | +97.7% | -4.9% |
| Total Assets | September 30, 2025 | $81.17M | -33.8% | -12.6% |
| Cash and Equivalents | September 30, 2025 | $42.39M | +2115.7% | -52.1% |
| Stockholders Equity | September 30, 2025 | $41.87M | +146.8% | -21.2% |
| R&D Expense | September 30, 2025 | $9.13M | -74.7% | +8.1% |
| Operating Income | September 30, 2025 | -$12.74M | +66.3% | -4.0% |
| Shares Outstanding | September 30, 2025 | 18.70M | -83.8% | +0.0% |
- Kalaris Therapeutics, Inc. reported Total Revenue of $165.0 thousand for fiscal year 2019.
- Kalaris Therapeutics, Inc. reported Revenue (ASC 606) of $165.0 thousand for fiscal year 2019.
- Kalaris Therapeutics, Inc. reported Net Income of -$43.44 million for fiscal year 2025.
- Kalaris Therapeutics, Inc. showed an increase of +37.2% in Net Income compared to the prior fiscal year.
- Kalaris Therapeutics, Inc. reported Diluted EPS of $2.85 per share (loss) for fiscal year 2025.
- Kalaris Therapeutics, Inc. showed an increase of +94.5% in Diluted EPS compared to the prior fiscal year.
- Kalaris Therapeutics, Inc. reported Total Assets of $121.74 million for fiscal year 2025.
- Kalaris Therapeutics, Inc. showed an increase of +1875.6% in Total Assets compared to the prior fiscal year.
- Kalaris Therapeutics, Inc. reported Cash and Equivalents of $98.05 million for fiscal year 2025.
- Kalaris Therapeutics, Inc. showed an increase of +5882.6% in Cash and Equivalents compared to the prior fiscal year.
- Kalaris Therapeutics, Inc. reported Stockholders Equity of $78.81 million for fiscal year 2025.
- Kalaris Therapeutics, Inc. showed an increase of +181.6% in Stockholders Equity compared to the prior fiscal year.
- Kalaris Therapeutics, Inc. reported R&D Expense of $30.75 million for fiscal year 2025.
- Kalaris Therapeutics, Inc. showed a decrease of -31.7% in R&D Expense compared to the prior fiscal year.
- Kalaris Therapeutics, Inc. reported Operating Income of -$46.15 million for fiscal year 2025.
- Kalaris Therapeutics, Inc. showed an increase of +10.8% in Operating Income compared to the prior fiscal year.
- Kalaris Therapeutics, Inc. reported Shares Outstanding of 22.90 million shares for fiscal year 2025.
- Kalaris Therapeutics, Inc. showed an increase of +1588.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: